Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.63 -3.54%
Revenue Growth %: +77,502.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +77,502.5%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.45 million.
Sees combined net product sales from both HETLIOZ® and Fanapt® $180 to $200 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Equity Residential (EQR) Tops Q1 EPS by 44c; offers guidance
- Texas Instruments (TXN) jumps as on earnings, revenue beat in fiscal Q1
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
